Kiora Pharmaceuticals Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
KPRX
- Investments
-
3
- Share Price
-
$0.82
- (As of Wednesday Closing)
Kiora Pharmaceuticals General Information
Description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact Information
Website
www.kiorapharma.comCorporate Office
- 169 Saxony Road
- Suite 212
- Encinitas, CA 92024
- United States
Corporate Office
- 169 Saxony Road
- Suite 212
- Encinitas, CA 92024
- United States
Kiora Pharmaceuticals Timeline
Kiora Pharmaceuticals Stock Performance
As of 18-Nov-2026, Kiora Pharmaceuticals’s stock price is $0.82. Its current market cap is $3.65M with 4.42M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.82 | $0.93 | $0.78 - $2.91 | $3.65M | 4.42M | 34.2K | -$2.68 |
Kiora Pharmaceuticals Financials Summary
As of 30-Sep-2026, Kiora Pharmaceuticals has a trailing 12-month revenue of $1M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (5,179) | (11,726) | (19,060) | (1,365) |
| Revenue | 1,000 | 0 | 16,000 | 0 |
| EBITDA | (13,805) | (12,967) | 4,448 | (12,531) |
| Net Income | (12,763) | (10,835) | 3,595 | (12,514) |
| Total Assets | 22,374 | 24,253 | 36,484 | 13,712 |
| Total Debt | 287 | 368 | 57 | 107 |
Kiora Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kiora Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Kiora Pharmaceuticals Comparisons
Industry
Financing
Details
Kiora Pharmaceuticals Competitors (11)
One of Kiora Pharmaceuticals’s 11 competitors is EyePoint, a Corporation company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| EyePoint | Corporation | Watertown, MA | ||||
| Foventa Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Limnopharma | Venture Capital-Backed | Granada, Spain | ||||
| Opus Genetics | Formerly VC-backed | Durham, NC | ||||
| Kodiak Sciences | Formerly VC-backed | Palo Alto, CA |
Kiora Pharmaceuticals Patents
Kiora Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023172818-A1 | Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor | Inactive | 09-Mar-2022 | ||
| WO-2023168176-A1 | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor | Inactive | 01-Mar-2022 | ||
| CA-3173160-A1 | Compositions and methods for treating ocular disease by contact lens mediated drug delivery | Pending | 25-Mar-2020 | ||
| EP-4125813-A1 | Compositions and methods for treating ocular disease by contact lens mediated drug delivery | Inactive | 25-Mar-2020 | ||
| US-20210299039-A1 | Compositions and methods for treating ocular disease by contact lens mediated drug delivery | Inactive | 25-Mar-2020 | A61K9/0051 |
Kiora Pharmaceuticals Signals
Kiora Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kiora Pharmaceuticals Acquisitions (3)
Kiora Pharmaceuticals’s most recent deal was a Merger/Acquisition with Bayon Therapeutics for . The deal was made on 21-Oct-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bayon Therapeutics | 21-Oct-2021 | Merger/Acquisition | Drug Discovery | ||
| Panoptes Pharma | 18-Dec-2020 | Merger/Acquisition | Drug Discovery | ||
| Jade Therapeutics | 07-Mar-2016 | Merger/Acquisition | Pharmaceuticals |
Kiora Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.43 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Kiora Pharmaceuticals FAQs
-
When was Kiora Pharmaceuticals founded?
Kiora Pharmaceuticals was founded in 1998.
-
Where is Kiora Pharmaceuticals headquartered?
Kiora Pharmaceuticals is headquartered in Encinitas, CA.
-
What is the size of Kiora Pharmaceuticals?
Kiora Pharmaceuticals has 13 total employees.
-
What industry is Kiora Pharmaceuticals in?
Kiora Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Kiora Pharmaceuticals a private or public company?
Kiora Pharmaceuticals is a Public company.
-
What is Kiora Pharmaceuticals’s stock symbol?
The ticker symbol for Kiora Pharmaceuticals is KPRX.
-
What is the current stock price of Kiora Pharmaceuticals?
As of 18-Nov-2026 the stock price of Kiora Pharmaceuticals is $0.82.
-
What is the current market cap of Kiora Pharmaceuticals?
The current market capitalization of Kiora Pharmaceuticals is $3.65M.
-
What is Kiora Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Kiora Pharmaceuticals is $1M.
-
Who are Kiora Pharmaceuticals’s competitors?
EyePoint, Foventa Therapeutics, Limnopharma, Opus Genetics, and Kodiak Sciences are some of the 11 competitors of Kiora Pharmaceuticals.
-
What is Kiora Pharmaceuticals’s annual earnings per share (EPS)?
Kiora Pharmaceuticals’s EPS for 12 months was -$2.68.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process